Labels

Non-Invasive Prenatal Testing: Challenges and Opportunities Ahead

The global non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025, according to a new report by Grand View Research, Inc. Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period.
In addition, presence of payers such as Anthem and Blue Shield of California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13, 18, and 21 is expected to impact the adoption rate of these tests, thereby resulting in increased revenue generation.
However, the projected NIPT-related price erosion in this market is expected to continue, thus intensifying competition amongst the operating participants, but restraining revenue generation to a certain extent.


Further Key Findings fromthe Report Suggest:
  • The market is segmented on the basis of the tests carried out during the gestation period as 0-12 weeks, 13-24 weeks, and 25-36 weeks
  • 13-24 weeks accounted for the largest share owing to the presence of maximum number of the tests carried out in this phase of pregnancy
  • High & average risk pregnancy held the larger share owing to presence of favorable payer reimbursement in this segment
  • Rising awareness pertaining to the prevention and screening of chromosomal anomalies, such as Down Syndrome is another factor anticipated to impact adoption
  • Asia Pacific is expected to register fastest year-on-year progress owing to the gradually increasing average maternal age, & increasing incidence of chromosomal aneuploidies
  • Some of the key players operating the market space include Natera, Inc;Illumina, Inc; Sequenom; Roche (Ariosa Diagnostics); Quest Diagnostics; and LabCorp
  • One of the key trends followed by companies includes licensing of the test to other labs and generating significant revenue by collecting royalty payments
  • Grand View Research has segmented the NIPT market on the basis of gestation period, and pregnancy risk level:
  • 0-12 weeks
  • 13-24 weeks
  • 25-36 weeks
  • High & Average Risk
  • Low Risk

Noninvasive Prenatal Testing Outlook, by Gestation Period (Revenue, USD Million, 2014 - 2025)
Noninvasive Prenatal Testing Outlook, by Pregnancy Risk Level (Revenue, USD Million, 2014 - 2025)
About Grand View Research:
Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 compnies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
Contact:
Grand View Research, Inc.
201 Spear Street 1100,
San Francisco, CA 94105
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Labels:

Comments

Post a Comment